JPH0775518B2 - Mushroom protein for eating and drinking, which is effective in preventing and treating hypertension, hyperlipidemia and obesity, and its extraction method - Google Patents

Description

DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention is extracted from Enokitake mushrooms of the order Hydrangeaceae Sarnopsis moss and Maitake mushrooms Enokitake,
Molecular weight of about 50,000 effective for prevention and treatment of hyperlipidemia and obesity
The present invention relates to a heat-unstable mushroom protein for eating and drinking and a method for extracting the same.

[Conventional technology]

Regarding components extracted from Maitake and Enoki mushroom, polysaccharides having an antitumor effect have been confirmed so far, and other medicinal effects have been suggested or handed down.

[Problems to be solved by the invention]

However, the components extracted from these Maitake mushrooms and the like include those that undergo heat treatment during the extraction process,
Only heat-stable components were extracted, and the above-mentioned medicinal effects were also obtained from such heat-stable components.

The present invention was devised in view of the current situation as described above, and the heat-labile components contained in Maitake and Enokitake, the effects of which have not been clarified so far, are taken out, and these components are further tested in various experiments. Was investigated to find out what kind of pharmacological effect it has, and among them, a mushroom protein that was particularly effective in the prevention and treatment of hypertension, hyperlipidemia, obesity was provided as a food or drink, and It also proposes a method of extracting the same.

[Means for solving problems]

In recent years, an extremely large number of research reports have been made on the pharmacological effects of the fungi, but as mentioned above, most of them are heat-stable components, and there are no reports on the pharmacological effects of heat-labile components. Little has been done. The present inventors have been studying the medicinal components contained in mushrooms, among the components contained in Maitake and Enoki mushroom in the heat-labile component in the water-eluted category,
From the experimental results described below, it was found that it has a very remarkable inhibitory effect on blood pressure elevation, serum lipid elevation and weight gain, and further has blood pressure lowering for hypertension, serum lipid lowering for hyperlipidemia and weight loss, and various studies have been conducted. Through the steps, the present invention was completed.

The active ingredients having these effects of the present invention can be extracted and separated from fruiting bodies or hyphae of Maitake and Enoki mushroom. The active ingredient can be obtained from the fruiting body of Maitake mushroom, for example, by the following method. That is, first, the fruit body of Maitake is dried, pulverized, and extracted with water to obtain a Maitake extract. As the extraction method, dried maitake fruit body pulverized product and water, 1 to 500 g of the pulverized product per 1 part of water
After suspending and contacting at room temperature or low temperature (0 to 40 ° C.) for 10 minutes or more, water-insoluble matter is separated by a press or the like to obtain an extract. Then, the extract is freeze-dried as it is, or concentrated under reduced pressure at 40 ° C or lower. The dried product was dissolved in approximately the same amount of water, the solution was dialyzed to remove low molecular weight substances, and the dialyzed solution was applied to a column using DEAE Sephadex (trade name of dextran gel manufactured by Pharmacia of Sweden) as a carrier. Sinks Adsorb active ingredients. 0.2 active ingredient adsorbed
Elute with a flow of molar sodium chloride. Ammonium sulfate was added to the obtained eluate up to 80% for salting out, the formed precipitate was collected by centrifugation, then the precipitate was dissolved in water, and the dissolved solution was separated into Sephadex G-100 (Pharmacia, Sweden). The active fraction is separated by molecular weight fractionation by gel filtration chromatography using a dextran gel (trade name of manufactured by Dextran Gel) as a carrier. The active fraction is concentrated and eluted in a section with a molecular weight of about 50,000. The collected active fraction is freeze-dried. This freeze-dried product is hereinafter referred to as mushroom protein.

The mushroom protein thus obtained is a fraction containing protein as a main component, and when ingested as a food or drink, it has a strong inhibitory effect on blood pressure increase, serum lipid increase, and weight gain. It also exhibits hypotensive blood pressure lowering, hyperlipidemia lowering serum lipids and weight loss. Also, these effects disappear by heating and contact with high-concentration ethanol.

According to the analysis of the present inventors, the mushroom protein of the present invention has the physicochemical properties described below, and from the results of the test using SHR rats described below, when ingested as food and drink, it has high blood pressure and high fat content. It is recognized as an effective substance for the prevention and treatment of blood and obesity.

Color and shape The mushroom protein extracted as a freeze-dried product is a porous light brown powder and has no taste or odor.

 Molecular weight: about 50,000 (measured by molecular weight fractionation method by gel filtration) pH of solution: 1% Aqueous solution has a pH of about 7.

Stability to heat Aqueous mushroom protein solutions are stable below 40 ° C. 40 ~ 70 ℃
Then, the rate of deactivation gradually increases and the rate of deactivation increases as the temperature rises. It rapidly deactivates above 70 ° C.

 Stability to ethanol Deactivates rapidly in 50% or more ethanol solution.

 Ultraviolet absorption Shows strong absorption at 280 nm.

Protein 98% (determined by the Lowry method using bovine serum albumin as a standard) Due to these properties, it has an inhibitory effect on blood pressure elevation, serum lipid elevation, and body weight gain.
As the name implies, the mushroom protein of the present invention, which has the effects of lowering serum lipids and reducing body weight in hyperlipidemia, is considered to be a protein.

〔Example〕

The present inventors have conducted various tests to clarify what kind of pharmacological action there is when the mushroom protein of the present invention is ingested as food or drink, and among them, a unique pharmacological effect was confirmed. The details will be described below.

Test Example 1 Mushroom protein extracted by the above-mentioned extraction method
Changes in body weight and blood pressure were examined when SHR rats were supplemented with 0.15% diet and fed to these rats at 6 to 10 weeks of age. The results are shown in FIGS. 1 and 2.

As shown in FIG. 1, the rats fed with the feed containing the mushroom protein of the present invention were suppressed in the increase in body weight. Further, as shown in FIG. 2, when the mushroom protein is added to the feed, it is understood that the rats fed with this mushroom have suppressed increase in blood pressure.

In addition, Table 1 below shows 10
The results obtained by collecting blood at the age of week and measuring serum lipids are shown.

As shown in the above table, it was revealed that the rats fed with the feed containing the mushroom protein of the present invention suppressed the elevation of serum lipid.

Similar results were obtained with mushroom proteins extracted from Mycelia or Enoki mushroom hyphae by a similar extraction method.

Test Example 2 SHR rats were fed a high-fat, high-calorie diet from the age of 5 to 15 weeks of age to make them hypertensive and obese, and a diet containing 0.3% of the mushroom protein obtained by the above-mentioned extraction method from the age of 15 weeks was added. The changes in body weight and blood pressure when examined up to 21 weeks of age were examined. The results are shown in FIGS. 3 and 4.

As shown in FIG. 3, SHR rats fed with the feed supplemented with the mushroom protein of the present invention clearly show a decrease in body weight. Further, as shown in FIG. 4, when the mushroom protein was added to the feed, the rats fed with the feed also showed a decrease in blood pressure.

In addition, Table 2 below shows that the test started at 15 weeks and the test ended.
The results obtained by collecting blood at the age of week and measuring serum lipids are shown.

From Table 2 above, it can be seen that the rats fed with the feed containing the mushroom protein of the present invention have lowered serum lipids.

It should be noted that quite similar results have been obtained for mushroom proteins extracted from hyphae of Maitake or Enoki mushroom by the same method as the above-mentioned extraction method.

〔The invention's effect〕

The mushroom protein of the present invention extracted as described above, as is clear from the above pharmacological test results, shows an excellent inhibitory action against blood pressure increase, serum lipid increase and body weight increase when ingested as a food or drink. It is clear that it also exhibits hypotensive hypotensive and hyperlipidemic serum lipid-lowering and weight-loss effects.

Since the edible mushroom protein having a molecular weight of about 50,000, which is effective for the prevention or treatment of hypertension, hyperlipidemia, and obesity of the present invention, is unstable to heat, it cannot be heated and the processing method is limited. As a method of eating and drinking, for example, it can be used for granular and tablet foods, powdered foods, encapsulated foods, alcoholic drinks, and tea-like drinks.

[Brief description of drawings]

FIG. 1 is a graph showing the change in body weight when diets containing the mushroom protein of the present invention and diets containing no mushroom protein were fed to SHR rats respectively and bred from 6 weeks old to 10 weeks old, FIG. Is a graph showing changes in blood pressure in the above case, and FIG. 3 is a high-fat, high-calorie diet that is raised from 5 weeks to 15 weeks of age to give high blood pressure and obesity,
Fig. 4 is a graph showing the change in body weight when the mushroom protein was added to the feed from the 15-week-old to the feed containing no mushroom protein up to the 21-week-old, and Fig. 4 is a graph showing the change in blood pressure in that case. Is.

─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. ⁶ Identification code Internal reference number FI Technical display location C07K 14/375 8318-4H C12P 21/00 A 9282-4B (C12P 21/00 C12R 1: 645) (56) References JP-A-2-270900 (JP, A) JP-A-59-196066 (JP, A) JP-A-60-23392 (JP, A) JP-A-60-186260 (JP, A) Kai 60-49758 (JP, A)

Claims (2)

[Claims] 1. A water extract obtained from a fruiting body or mycelium of Phellinus linteus or Enoki mushroom and dialyzed, and the dialyzed solution is subjected to ion exchange chromatography to be eluted with sodium chloride, and then salted out, and a water solution of the precipitate is obtained. By gel filtration chromatography
A mushroom protein for food and drink, which is effective for the prevention and treatment of hypertension, hyperlipidemia and obesity, consisting of 50,000 active fractions. 2. A water extract obtained from fruiting bodies or hyphae of Maitake or Enoki mushroom and dialyzed, and the dialyzed inner solution is subjected to ion exchange chromatography to elute with sodium chloride, followed by salting out, and a water solution of the precipitate. Is subjected to gel filtration chromatography to fractionate an active fraction having a molecular weight of about 50,000 into a molecular weight fraction, and a method for extracting a edible mushroom protein effective for prevention and treatment of hypertension, hyperlipidemia and obesity.